Korporativne novice
Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.
Teva Reports Fourth Quarter and Full Year 2011 Results
Fourth Quarter Net Revenues Total $5.7 Billion, up 28%, with Non-GAAP EPS of $1.59, up 27% Full Year 2011 Net Revenues Total $18.3 Billion, up 14%, with Non-GAAP EPS of $4.97, up 9% 25% Increase in Quarterly Dividend to NIS 1.00 Per Share JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter and year ended December 31, 2011. Q4 2011 Highlights: Net revenues of $5.7 billion, compared to $4.4 billion in the fourth quarter of 2010, an increase of 28%. Non-GAAP net inc...
Teva to Report Fourth Quarter and Full Year 2011 Financial Results on February 15, 2012
JERUSALEM--(BUSINESS WIRE)--Jan. 16, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2011 financial results on Wednesday, February 15, 2012. Teva will host a conference call and live webcast on the same day, at 8:30 a.m. ET to discuss its fourth quarter and full year 2011 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-877-407-0784; International 1-201-689-8560; Israel and the United Kingdom 00-800-224-62666. A liv...
Teva to Present at the 30th Annual J.P. Morgan Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer, and William Marth, President & CEO, Teva Pharmaceuticals – Americas, will present on Tuesday, January 10, 2012. What: Teva Presentation at the 30th Annual J.P. Morgan Healthcare Conference Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. & William Marth, President and CEO, Teva Pharmaceuticals - Americas When: Tuesday, January 10, 2012 at 9:30 a.m. (PST) Where: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A...
Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE®
Study Findings Published in Frontiers in Bioscience JERUSALEM, Jan 03, 2012 (BUSINESS WIRE) --Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE® (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio (MTR). Magnetization transfer ratio is a nonconventional MRI technique used to investigate abnormalities in brain structures, and increased values indicate potential remyelination and axonal tissue repair. The 12-month MRI study, conducted at the Buffalo Neuroimaging Analysis Center ...
Teva Announces Management Succession
Dr. Jeremy Levin, A Former Senior Executive at Bristol-Myers Squibb, To Succeed Shlomo Yanai as President and CEO JERUSALEM--(BUSINESS WIRE)--Jan. 1, 2012-- Phillip Frost, MD, Chairman of the Board of Directors of Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA), announced today that Shlomo Yanai, President and CEO of Teva, plans to retire from the company effective May 2012, and that as part of a succession plan, the Board of Directors has named Dr. Jeremy Levin, a former senior executive at Bristol-Myers Squibb (NYSE:BMY), to succeed him at that time. The plan is the result of a decision by Mr. Yanai to move on to a new phase in his career after five years as President and CEO of Teva...
